BACKGROUND: Closed-loop control of type 1 diabetes is receiving increasing attention due to advancement in glucose sensor and insulin pump technology. Here the function and structure of a class of control algorithms designed to exert control to range, defined as insulin treatment optimizing glycemia within a predefined target range by preventing extreme glucose fluctuations, are studied. METHODS: The main contribution of the article is definition of a modular architecture for control to range. Emphasis is on system specifications rather than algorithmic realization. The key system architecture elements are two interacting modules: range correction module, which assesses the risk for incipient hyper- or hypoglycemia and adjusts insulin rate accordingly, and safety supervision module, which assesses the risk for hypoglycemia and attenuates or discontinues insulin delivery when necessary. The novel engineering concept of range correction module is that algorithm action is relative to a nominal open-loop strategy-a predefined combination of basal rate and boluses believed to be optimal under nominal conditions. RESULTS: A proof of concept of the feasibility of our control-to-range strategy is illustrated by using a prototypal implementation tested in silico on patient use cases. These functional and architectural distinctions provide several advantages, including (i) significant insulin delivery corrections are only made if relevant risks are detected; (ii) drawbacks of integral action are avoided, e.g., undershoots with consequent hypoglycemic risks; (iii) a simple linear model is sufficient and complex algorithmic constraints are replaced by safety supervision; and (iv) the nominal profile provides straightforward individualization for each patient. CONCLUSIONS: We believe that the modular control-to-range system is the best approach to incremental development, regulatory approval, industrial deployment, and clinical acceptance of closed-loop control for diabetes. 2009 Diabetes Technology Society.
BACKGROUND: Closed-loop control of type 1 diabetes is receiving increasing attention due to advancement in glucose sensor and insulin pump technology. Here the function and structure of a class of control algorithms designed to exert control to range, defined as insulin treatment optimizing glycemia within a predefined target range by preventing extreme glucose fluctuations, are studied. METHODS: The main contribution of the article is definition of a modular architecture for control to range. Emphasis is on system specifications rather than algorithmic realization. The key system architecture elements are two interacting modules: range correction module, which assesses the risk for incipient hyper- or hypoglycemia and adjusts insulin rate accordingly, and safety supervision module, which assesses the risk for hypoglycemia and attenuates or discontinues insulin delivery when necessary. The novel engineering concept of range correction module is that algorithm action is relative to a nominal open-loop strategy-a predefined combination of basal rate and boluses believed to be optimal under nominal conditions. RESULTS: A proof of concept of the feasibility of our control-to-range strategy is illustrated by using a prototypal implementation tested in silico on patient use cases. These functional and architectural distinctions provide several advantages, including (i) significant insulin delivery corrections are only made if relevant risks are detected; (ii) drawbacks of integral action are avoided, e.g., undershoots with consequent hypoglycemic risks; (iii) a simple linear model is sufficient and complex algorithmic constraints are replaced by safety supervision; and (iv) the nominal profile provides straightforward individualization for each patient. CONCLUSIONS: We believe that the modular control-to-range system is the best approach to incremental development, regulatory approval, industrial deployment, and clinical acceptance of closed-loop control for diabetes. 2009 Diabetes Technology Society.
Authors: Daniela Bruttomesso; Anne Farret; Silvana Costa; Maria Cristina Marescotti; Monica Vettore; Angelo Avogaro; Antonio Tiengo; Chiara Dalla Man; Jerome Place; Andrea Facchinetti; Stefania Guerra; Lalo Magni; Giuseppe De Nicolao; Claudio Cobelli; Eric Renard; Alberto Maran Journal: J Diabetes Sci Technol Date: 2009-09-01
Authors: Lalo Magni; Marco Forgione; Chiara Toffanin; Chiara Dalla Man; Boris Kovatchev; Giuseppe De Nicolao; Claudio Cobelli Journal: J Diabetes Sci Technol Date: 2009-09-01
Authors: Lalo Magni; Davide M Raimondo; Luca Bossi; Chiara Dalla Man; Giuseppe De Nicolao; Boris Kovatchev; Claudio Cobelli Journal: J Diabetes Sci Technol Date: 2007-11
Authors: Stuart A Weinzimer; Garry M Steil; Karena L Swan; Jim Dziura; Natalie Kurtz; William V Tamborlane Journal: Diabetes Care Date: 2008-02-05 Impact factor: 19.112
Authors: Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski Journal: Transplantation Date: 2016-02 Impact factor: 4.939
Authors: Gregory P Forlenza; Sunil Deshpande; Trang T Ly; Daniel P Howsmon; Faye Cameron; Nihat Baysal; Eric Mauritzen; Tatiana Marcal; Lindsey Towers; B Wayne Bequette; Lauren M Huyett; Jordan E Pinsker; Ravi Gondhalekar; Francis J Doyle; David M Maahs; Bruce A Buckingham; Eyal Dassau Journal: Diabetes Care Date: 2017-06-05 Impact factor: 19.112
Authors: Gregory P Forlenza; Laya Ekhlaspour; Marc Breton; David M Maahs; R Paul Wadwa; Mark DeBoer; Laurel H Messer; Marissa Town; Jennifer Pinnata; Geoff Kruse; Bruce A Buckingham; Daniel Cherñavvsky Journal: Diabetes Technol Ther Date: 2019-03-19 Impact factor: 6.118
Authors: Howard Zisser; Eric Renard; Boris Kovatchev; Claudio Cobelli; Angelo Avogaro; Revital Nimri; Lalo Magni; Bruce A Buckingham; H Peter Chase; Francis J Doyle; John Lum; Peter Calhoun; Craig Kollman; Eyal Dassau; Anne Farret; Jerome Place; Marc Breton; Stacey M Anderson; Chiara Dalla Man; Simone Del Favero; Daniela Bruttomesso; Alessio Filippi; Rachele Scotton; Moshe Phillip; Eran Atlas; Ido Muller; Shahar Miller; Chiara Toffanin; Davide Martino Raimondo; Giuseppe De Nicolao; Roy W Beck Journal: Diabetes Technol Ther Date: 2014-07-08 Impact factor: 6.118
Authors: H Peter Chase; Francis J Doyle; Howard Zisser; Eric Renard; Revital Nimri; Claudio Cobelli; Bruce A Buckingham; David M Maahs; Stacey Anderson; Lalo Magni; John Lum; Peter Calhoun; Craig Kollman; Roy W Beck Journal: Diabetes Technol Ther Date: 2014-09-04 Impact factor: 6.118
Authors: Daniel P Howsmon; Nihat Baysal; Bruce A Buckingham; Gregory P Forlenza; Trang T Ly; David M Maahs; Tatiana Marcal; Lindsey Towers; Eric Mauritzen; Sunil Deshpande; Lauren M Huyett; Jordan E Pinsker; Ravi Gondhalekar; Francis J Doyle; Eyal Dassau; Juergen Hahn; B Wayne Bequette Journal: J Diabetes Sci Technol Date: 2018-02-01